Sugi Predict

Sugi Predict / Targets / CCNY

CCNY

Cyclin-Y (Cyc-Y) (Cyclin box protein 1) (Cycl · Q8ND76 · CCNY on Sugi Atlas →

5,996 patent compounds predicted against CCNY, 4,356 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL3936062 SCHEMBL3936062 0.52 18/20
SCHEMBL4996737 SCHEMBL4996737 0.56 17/20
SCHEMBL8262703 SCHEMBL8262703 0.52 17/20
SCHEMBL8262563 SCHEMBL8262563 0.51 17/20
SCHEMBL8261494 SCHEMBL8261494 0.53 16/20
SCHEMBL8261343 SCHEMBL8261343 0.52 15/20
SCHEMBL13993691 SCHEMBL13993691 0.49 15/20
SCHEMBL8263051 SCHEMBL8263051 0.52 14/20
SCHEMBL13993665 SCHEMBL13993665 0.50 14/20
At-7519 At-7519 (SCHEMBL1069453) 0.59 13/20
SCHEMBL2031219 SCHEMBL2031219 0.51 13/20
SCHEMBL1286714 SCHEMBL1286714 0.48 13/20
SCHEMBL8263078 SCHEMBL8263078 0.48 13/20
At-7519 At-7519 (SCHEMBL1072294) 0.58 12/20
SCHEMBL2425448 SCHEMBL2425448 0.55 12/20
SCHEMBL8263999 SCHEMBL8263999 0.52 12/20
SCHEMBL13993707 SCHEMBL13993707 0.49 12/20
SCHEMBL13993661 SCHEMBL13993661 0.52 11/20
SCHEMBL13993706 SCHEMBL13993706 0.48 11/20
At-7519 At-7519 (SCHEMBL955568) 0.64 10/20

Clinical trials — most relevant to CCNY by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer PHASE3RECRUITING
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) PHASE3COMPLETED
Cyclin Dependant Kinase 4/6 (CDK4/6) Inhibitors as a Second Line Treatment in Metastatic Breast Cancer Patients PHASE3UNKNOWN
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas PHASE2RECRUITING
Histology-Independent Study of Palbociclib in Patients With Advanced Cancer PHASE2WITHDRAWN
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer PHASE2UNKNOWN
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression PHASE2COMPLETED
BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors PHASE2WITHDRAWN
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer PHASE2RECRUITING
Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer PHASE2COMPLETED
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6 PHASE2RECRUITING
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors PHASE1/PHASE2COMPLETED
LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE) PHASE2COMPLETED
Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors PHASE2RECRUITING
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) PHASE1/PHASE2RECRUITING
Abemaciclib + Pembrolizumab In Glioblastoma PHASE2WITHDRAWN
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms PHASE1COMPLETED
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors PHASE1RECRUITING
Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer PHASE1ACTIVE_NOT_RECRUITING
Erlotinib in Treating Patients With Barrett Esophagus PHASE1UNKNOWN
the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy nanUNKNOWN
BLESSED: Expanded Access for DNG64-CAR-V for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast nanAVAILABLE
A Clinical Evaluation of Everolimus Eluting Coronary Stents in the Treatment of Patients With ST-segment Elevation Myocardial Infarction: EXAMINATION Study nanCOMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Study of Tissue and Blood Samples From Patients With Low-Grade Glioma nanCOMPLETED
The Use of Immunohistochemical Staining for the Prediction of Wilms Tumour Progression and Recurrence nanUNKNOWN
Protein Expression in Tumor Tissue Samples From Patients With Cancer of the Oropharynx nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CCNY binder may also engage these)

ProteinNameSimilarity
P34624 — 1.000 P34624 →
Q6NRF4 — 1.000 Q6NRF4 →
Q08CI4 — 1.000 Q08CI4 →
Q5U5D0 — 0.998 Q5U5D0 →
Q4R871 — 0.996 Q4R871 →
Q5T2Q4 — 0.992 Q5T2Q4 →
Q22695 — 0.989 Q22695 →
I2HAA0 — 0.989 I2HAA0 →
D3YUJ3 — 0.988 D3YUJ3 →
P30645 — 0.988 P30645 →
A2A3K4 — 0.987 A2A3K4 →
G5EFD2 — 0.987 G5EFD2 →
A0A8V8TMC4 — 0.987 A0A8V8TMC4 →
O01501 — 0.986 O01501 →
O14328 — 0.985 O14328 →
Q12477 — 0.985 Q12477 →
Q9VM91 — 0.985 Q9VM91 →
Q5ICL9 — 0.985 Q5ICL9 →
Q95TJ9 — 0.985 Q95TJ9 →
Q9XYB7 — 0.984 Q9XYB7 →
O17611 — 0.984 O17611 →
P24867 — 0.984 P24867 →
A6ZZF6 — 0.984 A6ZZF6 →
Q9M0E5 — 0.984 Q9M0E5 →
P34638 — 0.984 P34638 →
Q6ING4 — 0.984 Q6ING4 →
A8KBE0 — 0.984 A8KBE0 →
O01326 — 0.984 O01326 →
A6H8I2 — 0.984 A6H8I2 →
Q60L58 — 0.983 Q60L58 →